On March 17, 2025, Senators Chuck Grassley (R-IA), John Cornyn (R-TX), Richard Blumenthal (D-CT), and Richard Durbin (D-IL) re-introduced the “Affordable Prescriptions for Patients Act” (“APPA”), which previously passed the U.S. Senate as S.150 in the 2024 Congressional session, but was not passed by the House. On April 3, 2025, the Committee on the Judiciary ordered the bill to be reported favorably without amendment. The APPA limits the number of patents that can be asserted by a reference product sponsor (“RPS”) against a biosimilar manufacturer in Biologics Price Competition and Innovation Act (“BPCIA”) litigations under 35 U.S.C. § 271(e).
Please see full publication below for more information.
